The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 20, 2018
Filed:
Oct. 17, 2014
Applicants:
Zealand Pharma A/s, Glostrup, DK;
Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;
Inventors:
Ditte Riber, Brønshøj, DK;
Jakob Lind Tolborg, Herlev, DK;
Dieter Wolfgang Hamprecht, Pozzolengo, IT;
Wolfgang Rist, Ingelheim Am Rhein, DE;
Assignee:
Zealand Pharma A/S, Glostrup, DK;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/605 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/198 (2006.01); A61K 31/485 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/198 (2013.01); A61K 31/485 (2013.01); A61K 31/7048 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01);
Abstract
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.